For research use only. Not for therapeutic Use.
Triaziquone（Cat No.:I009876）is a synthetic anticancer agent that belongs to the class of aziridinylbenzoquinones. It functions by forming DNA crosslinks, which inhibit DNA replication and transcription, ultimately leading to cell death. Triaziquone has demonstrated activity against various cancer types, including leukemia and solid tumors, in preclinical studies. Its mechanism of action, involving the generation of DNA damage, makes it similar to other alkylating agents, but with distinct properties that may offer potential advantages in certain treatment regimens. Clinical development of triaziquone has been limited, but it remains of interest in cancer research for its targeted cytotoxic effects.
| Catalog Number | I009876 |
| CAS Number | 68-76-8 |
| Synonyms | A 163; A 163; A 163; Triaziquone; Trenimon; Trenimone; Triazichon;2,3,5-tri(aziridin-1-yl)cyclohexa-2,5-diene-1,4-dione |
| Molecular Formula | C12H13N3O2 |
| Purity | ≥95% |
| Target | DNA/RNA Synthesis |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| IUPAC Name | 2,3,5-tris(aziridin-1-yl)cyclohexa-2,5-diene-1,4-dione |
| InChI | InChI=1S/C12H13N3O2/c16-9-7-8(13-1-2-13)12(17)11(15-5-6-15)10(9)14-3-4-14/h7H,1-6H2 |
| InChIKey | PXSOHRWMIRDKMP-UHFFFAOYSA-N |
| SMILES | C1CN1C2=CC(=O)C(=C(C2=O)N3CC3)N4CC4 |
| Reference | </br>1:A study on inhibition mechanism of breast cancer cells by bis-type triaziquone. Lin YL, Su YT, Chen BH.Eur J Pharmacol. 2010 Jul 10;637(1-3):1-10. doi: 10.1016/j.ejphar.2010.03.034. Epub 2010 Apr 2. PMID: 20371239 </br>2:Synthesis and antitumor evaluation of novel bis-triaziquone derivatives. Huang CH, Kuo HS, Liu JW, Lin YL.Molecules. 2009 Jun 29;14(7):2306-16. doi: 10.3390/molecules14072306. PMID: 19633605 Free Article</br>3:A sequential analysis of meiosis in the male mouse using a restricted spermatocyte population obtained by a hydroxyurea/triaziquone treatment. Oud JL, de Jong JH, de Rooij DG.Chromosoma. 1979 Feb 21;71(2):237-48. PMID: 371933 </br>4:A sequential screening of the cytogenetic damage induced by triaziquone. Oud JL, Peters PW.Mutat Res. 1978 Oct;54(2):175-84. PMID: 362189 </br>5:Comparisons of the chemical and biologic properties of triaziquone and triaziquone-protein conjugates. Linford JH, Froese G.J Natl Cancer Inst. 1978 Feb;60(2):307-16. PMID: 74416 </br>6:Effects of caffeine on sister chromatid exchange (SCE) after exposure to UV light or triaziquone studied with a fluorescence plus giemsa (FPG) technique. Vogel W, Bauknecht T.Hum Genet. 1978 Jan 19;40(2):193-8. PMID: 624547 </br>7:Chromosome aberrations in metaphase II oocytes of Chinese hamster (Cricetulus griseus). I. The sensitivity of the pre-ovulatory phase to triaziquone. Hansmann I, Neher J, Röhrborn G.Mutat Res. 1974 Dec;25(3):347-59. No abstract available. PMID: 4437573 </br>8:Induced dominant lethals in female mice: effects of triaziquone and phenylbutazone. Machemer L, Hess R.Experientia. 1973 Feb 15;29(2):190-2. No abstract available. PMID: 4692764 </br>9:[Comparative studies using the urine metabolites of cyclophosphamide, bis-(2-chloroethyl)amine and triaziquone on Lactobacillus fermenti ATCC 9338]. Norpoth K, Modlich W, Schumacher H, Rauen HM.Arzneimittelforschung. 1972 Oct;22(10):1784-8. German. No abstract available. PMID: 4677072 </br>10:[Study on the reproducibility of the dominant lethal test in the mouse using cyclophosphamide and triaziquone]. Machemer L, Stenger EG.Arzneimittelforschung. 1971 Jul;21(7):1037-9. German. No abstract available. PMID: 5109493 |
